BRPI0412869A - use of a tissue-protecting erythropoietin or cytokine, and method for protecting or maintaining the viability of a responsive mammalian cell, tissue or organ - Google Patents
use of a tissue-protecting erythropoietin or cytokine, and method for protecting or maintaining the viability of a responsive mammalian cell, tissue or organInfo
- Publication number
- BRPI0412869A BRPI0412869A BRPI0412869-9A BRPI0412869A BRPI0412869A BR PI0412869 A BRPI0412869 A BR PI0412869A BR PI0412869 A BRPI0412869 A BR PI0412869A BR PI0412869 A BRPI0412869 A BR PI0412869A
- Authority
- BR
- Brazil
- Prior art keywords
- tissue
- protecting
- erythropoietin
- organ
- viability
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title abstract 3
- 108090000394 Erythropoietin Proteins 0.000 title abstract 3
- 229940105423 erythropoietin Drugs 0.000 title abstract 3
- 210000000056 organ Anatomy 0.000 title abstract 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 3
- 102000004127 Cytokines Human genes 0.000 title abstract 2
- 108090000695 Cytokines Proteins 0.000 title abstract 2
- 210000004962 mammalian cell Anatomy 0.000 title abstract 2
- 230000002633 protecting effect Effects 0.000 title abstract 2
- 210000001519 tissue Anatomy 0.000 title abstract 2
- 230000035899 viability Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002669 organ and tissue protective effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001012 protector Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"USO DE UMA ERITROPOIETINA OU UMA CITOCINA PROTETORA DE TECIDO, E, MéTODO PARA PROTEGER OU MANTER A VIABILIDADE DE UMA CéLULA, TECIDO OU ORGãO MAMìFEROS RESPONSIVOS". Os métodos e usos são fornecidos para uma composição farmacêutica com uma eritropoietina ou uma citocina protetora de tecido para proteger ou restaurar a função para uma função ou viabilidade de célula, tecido, orgão ou parte do corpo responsivos em mamíferos quando administrada fora da janela terapêutica de produtos terapêuticos previamente aprovados."USE OF A TISSUE PROTECTOR ERYTHROPOIETIN OR CYTOKIN, AND METHOD FOR PROTECTING OR MAINTAINING THE FEASIBILITY OF A RESPONSIVE MAMMAL CELL, TISSUE OR ORGAN". The methods and uses are provided for a pharmaceutical composition with an erythropoietin or tissue protective cytokine to protect or restore function to a responsive mammalian cell, tissue, organ or body function or viability when administered outside the therapeutic window of previously approved therapeutic products.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2004/015863 WO2005117927A2 (en) | 2004-05-20 | 2004-05-20 | Tissue protective cytokines with an extended therapeutic window |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0412869A true BRPI0412869A (en) | 2006-10-03 |
Family
ID=35463339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0412869-9A BRPI0412869A (en) | 2004-05-20 | 2004-05-20 | use of a tissue-protecting erythropoietin or cytokine, and method for protecting or maintaining the viability of a responsive mammalian cell, tissue or organ |
Country Status (7)
| Country | Link |
|---|---|
| CN (1) | CN1897960A (en) |
| AU (1) | AU2004319797A1 (en) |
| BR (1) | BRPI0412869A (en) |
| IL (1) | IL172036A0 (en) |
| IS (1) | IS8222A (en) |
| NO (1) | NO20062506L (en) |
| WO (1) | WO2005117927A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| WO2019072411A1 (en) * | 2017-10-10 | 2019-04-18 | Augustinus Bader | Erythropoietin (epo) application in spinal cord injury (sci) therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
| US20040091961A1 (en) * | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
| NZ542092A (en) * | 2003-03-27 | 2008-04-30 | Janssen Pharmaceutica Nv | Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime |
-
2004
- 2004-05-20 CN CNA200480038280XA patent/CN1897960A/en active Pending
- 2004-05-20 WO PCT/US2004/015863 patent/WO2005117927A2/en not_active Ceased
- 2004-05-20 AU AU2004319797A patent/AU2004319797A1/en not_active Abandoned
- 2004-05-20 BR BRPI0412869-9A patent/BRPI0412869A/en not_active IP Right Cessation
-
2005
- 2005-11-17 IL IL172036A patent/IL172036A0/en unknown
-
2006
- 2006-01-10 IS IS8222A patent/IS8222A/en unknown
- 2006-05-31 NO NO20062506A patent/NO20062506L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IS8222A (en) | 2006-01-10 |
| AU2004319797A8 (en) | 2008-12-11 |
| AU2004319797A1 (en) | 2006-01-12 |
| CN1897960A (en) | 2007-01-17 |
| NO20062506L (en) | 2006-05-31 |
| IL172036A0 (en) | 2009-02-11 |
| WO2005117927A2 (en) | 2005-12-15 |
| WO2005117927A3 (en) | 2006-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312395A (en) | recombinant mutein protective tissue cytokine, mammalian cell responsive recombinant tissue protective cytokine, isolated nucleic acid molecule, vector, expression vector, genetically engineered cell, cell, pharmaceutical composition, method for protecting, maintaining or enhancing the viability of a cell, tissue or organ isolated from a mammalian body, use of a recombinant tissue protective cytokine, method for facilitating the transcytosis of a molecule through an endothelial cell barrier in a mammal, and composition for transporting a molecule through of transcytosis through an endothelial cell barrier | |
| BRPI0410470A (en) | use of a tissue-protecting erythropoietin or cytokine and method for protecting or maintaining the viability of a mammalian cell, tissue or organ responding | |
| PL377146A1 (en) | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs | |
| SV2002000245A (en) | SUBSTITUTED OXAZOLIDINONES AND ITS USE REF. READ 34122-SV | |
| BR0108173A (en) | Botulinum toxin pharmaceutical compositions | |
| FI953748A0 (en) | Compounds with both potent calcium antagonist and antioxidant activity and their use as cell protective agents | |
| NO20050497L (en) | Use of CETP inhibitors and optionally HMG COA reducible inhibitors and / or antihypertensive agents | |
| BRPI0412526A (en) | compound, use of a compound, pharmaceutical composition, pharmaceutical aerosol formulation, and method for treating a human or animal patient with an anti-inflammatory and / or allergic condition | |
| BRPI0912411A8 (en) | use of a human interleukin-2 mutein (hil-2 mutein) or a fragment thereof, pharmaceutical composition for the treatment and / or prophylaxis of an autoimmune disease, use of human interleukin-2 mutein (hil-2 mutein) 2) or a section thereof, for the formation of regulatory t cells (treg) in an organism, method for treatment and / or prophylaxis of an autoimmune disease in an organism, method for formation of regulatory t cells (treg) in an organism organism, method for formation of regulatory t cells (treg) in vitro. | |
| BR0312506A (en) | Botulinum toxin transdermal compositions | |
| DK1331927T3 (en) | Topical composition containing at least one vitamin D or vitamin D analogue and at least one dietary chosteroid | |
| BR0113663A (en) | Pectin Film Compositions | |
| CR9351A (en) | COMPOSITIONS AND METHODS FOR TOPICA APPLICATION AND TRANSDERMIC SUPPLY OF BOTULIN TOXIN | |
| BR0212026A (en) | Fentanyl or similar transdermal therapeutic system | |
| AR069665A1 (en) | COMPOSITIONS TO MODEL HAIR AND METHODS OF USE | |
| FR2746101B1 (en) | BICYCLIC-AROMATIC COMPOUNDS | |
| DK0823903T3 (en) | Heterocyclic biaryl compounds, pharmaceutical preparations and cosmetic compositions containing them, and uses | |
| BR0311866A (en) | Saponin or sapogenin compositions for cancer therapy | |
| ATE198467T1 (en) | DIAROMATIC PROPYNYL OR DIENYL COMPOUNDS | |
| BRPI0412869A (en) | use of a tissue-protecting erythropoietin or cytokine, and method for protecting or maintaining the viability of a responsive mammalian cell, tissue or organ | |
| FR2915397B1 (en) | PHARMACEUTICAL AND / OR COSMETIC COMPOSITION CONTAINING ACTIVE ACONITASE ACTIVATOR PRINCIPLES | |
| ATE517121T1 (en) | INTEGRIN HETERODIMER AND AN ALPHA SUBUNIT THEREOF | |
| DE69717311D1 (en) | COSMETIC, DERMATOLOGICAL AND PHARMACEUTICAL APPLICATION OF A TERMINALIA CATAPPA PLANT EXTRACT | |
| BR0208860A (en) | Use of a cationic dextran derivative, method for protecting an individual against dose-limiting organ damage, and method for protecting an individual against renal damage | |
| NO20050247L (en) | Low molecular weight oversulfated polysaccharide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |